Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study

Okada, Takenori; Saotome, Takashi; Nagao, Toshitaka; Masubuchi, Tatsuo; Fushimi, Chihiro; Matsuki, Takashi; Takahashi, Hideaki; Miura, Kouki; Tsukahara, Kiyoaki; Tada, Yuichiro

doi:10.21873/invivo.11549

Cited by 20 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 40 SDC patients were treated with chemotherapy in these studies. In two studies patients were treated with a combination of carboplatin and a taxane (docetaxel/paclitaxel) [46,49]. The combination of carboplatin and paclitaxel (N = 18) resulted in objective responses in 39% of the patients, and the combination of carboplatin with docetaxel (N = 12) resulted in objective response in 50%.…”

Section: Chemotherapymentioning

confidence: 99%

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Uijen¹,

Lassche²,

Grunsven³

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Background: Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland cancer. Approximately half of SDC patients will develop recurrences or metastases. Therapeutic palliative therapy is therefore often needed. The majority of SDC tumors expresses the androgen receptor (AR) and one-third expresses human epidermal growth factor receptor 2 (HER2), both are potential therapeutic targets. The aim of this paper is to systematically review and summarize the evidence on systemic palliative therapy for SDC and to provide treatment recommendations. Materials and methods: Electronic libraries were systematically searched with a broad search strategy to identify studies where SDC patients received systemic therapy. Due to the rarity of SDC no restrictions were placed on study designs. Results: The search resulted in 2014 articles of which 153 were full-text analyzed. Forty-five studies were included in the analysis, which included in total 256 SDC patients receiving systemic therapy. Two phase 2 trials primarily including SDC patients were identified. The majority of the studies were case series or case reports, resulting in an overall low quality of available evidence. Based on studies including ≥ 5 SDC patients, objective responses to HER2 targeting agents were observed in 60-70%, to AR pathway agents in 18-53% and to chemotherapy in 10-50%. Conclusion: For AR or HER2 positive SDC, agents targeting these pathways are the cornerstone for palliative treatment. Regarding chemotherapy, the combination of carboplatin combined with a taxane is best studied. Regarding other targeted agents and immunotherapy evidence is anecdotal, limiting formulation of treatment recommendations for these antineoplastic agents.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Uijen¹,

Lassche²,

Grunsven³

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…The major challenge for treatment of locally advanced, recurrent, or metastatic SGC is its resistance to systemic chemotherapy therapy (12). Unfortunately, the effectiveness of EGFR-targeted therapy (e.g., cetuximab) for SGC has not been sufficiently proven (9,(13)(14)(15).…”

Section: Discussionmentioning

confidence: 99%

Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

Nakano

Yasumatsu

Hashimoto

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5fluorouracil plus cetuximab (EXTREME). Patients and Methods: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. Results: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. Conclusion: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.Recurrent, locally advanced or distant metastatic salivary gland cancer (SGC) has no established systemic therapy. Surgical resection followed by radiation therapy is sometimes performed for SGC of advanced stage or with poor prognostic factors (1). SGC has different kinds of histopathological subtypes and three grading systems (2, 3), so it is frequently difficult to choose an optimum treatment.Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that has an important role in tumor growth and progression in various kinds of cancer and serves as a therapeutic target of molecular targeted therapy (e.g., cetuximab) (4, 5). In fact, the EXTREME regimen (cisplatin/carboplatin, 5-fluorouracil plus cetuximab) is 979 This article is freely accessible online.

show abstract

“…Standard single-agent or combination chemotherapy regimens have low response rates with significant hematologic, cardiac, and neurologic toxicities. For those eligible, the response rates of nearly 40% have been seen with combination regimens including cyclophosphamide, doxorubicin, and cisplatin (CAP); carboplatin and paclitaxel; and carboplatin and docetaxel [5][6][7][8].…”

Section: Discussionmentioning

confidence: 99%

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective: Rare disease Background: Salivary duct carcinoma (SDC) is a rare, aggressive head and neck cancer with frequent metastases. Current treatment options for recurrent or metastatic SDC include targeted anti-androgen therapy, HER2-targeted therapy, or systemic chemotherapy. We report the first use of a combination chemohormonal strategy. Case Report: A 68-year-old male who had never smoked with a past medical history of two-vessel coronary artery disease and systolic heart failure presented with a parotid mass and underwent surgical resection. Biopsy of the mass revealed high-grade, androgen receptor-positive and Erb-B2 receptor tyrosine kinase-2 (ERBB2)-amplified positive SDC. He subsequently received adjuvant radiation therapy. Four months after completion of adjuvant radiation therapy, recurrence with symptomatic pleural effusion and nodes, hepatic metastases, and boney metastases occurred. Due to significant symptomatic tumor, a rapid treatment response was desired. Combination chemohormonal therapy (CHT) was initiated with carboplatin area under the curve 4 and paclitaxel, 200 mg/m 2 in 21day cycles along with combined androgen blockade using leuprolide, 45 mg subcutaneously every 6 months and bicalutamide, 50 mg daily. The treatment was well tolerated with fatigue as the main adverse event. Positron emission tomography-computed tomography at 3 and 6 months after treatment initiation showed good partial response. The patient experienced uveal progression after 8 months and alternate treatment was started. Conclusions: Combination CHT with carboplatin, paclitaxel, and combined androgen deprivation may be a good treatment option in androgen receptor-positive recurrent or metastatic SDC if rapid treatment response is desired. Combination chemotherapy with androgen deprivation for validation through clinical trials.

show abstract

Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study

Cited by 20 publications

References 31 publications

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma

Contact Info

Product

Resources

About